Sie befinden sich hier




The overall goal of GRK 2727 is to uncover checkpoints in innate immune cells at the transcriptional, post- transcriptional, metabolic and cell-surface receptor levels, and to validate their functions in cancer and conditions of tissue damage.

Topics of GRK 2727:

We focus on Natural Killer (NK) cells and monocytes/macrophages that function at the forefront of immune responses. We expect that the obtained mechanistic knowledge will be instrumental for the design of innovative therapies of cancer and in conditions of tissue damage, where these checkpoints could be therapeutically blocked or fostered, respectively. Consortium members benefit from complementary expertise in innate immunity, a common focus on complex immune processes, and from sharing cutting-edge experimental methods including sophisticated single-cell RNAseq analyses, proteomics, metabolomics and multiparameter flow cytometry. Our goals are tackled by interdisciplinary collaborations of experts in different fields of innate immunity and with structured cooperations between basic and clinical researchers. To benefit from complementary expertise in innate immunity, GRK 2727 collaborates with pioneers in the field of innate immunity from the Karolinska Institute (KI) in Stockholm and Vienna University.


GRK 2727/1 InCheck
„Innate Immune Checkpoints in Cancer and Tissue Damage"

TPMA2, 2. OG
Franz-Volhard-Str. 6
68167 Mannheim

Phone +49 621 383-71509
Fax +49 621 383-71506
Twitter GRK 2727: @grk2727